Specific vaccine for treating or preventing primary liver cancer and preparation method thereof

By extracting whole-membrane proteins from patients' autologous liver cancer cells combined with aluminum hydroxide adjuvant, a specific vaccine was prepared, which solved the side effects and high recurrence rates in liver cancer treatment, significantly improved the immune response and survival period, and achieved liver cancer effective treatment and prevention.

CN119015402APending Publication Date: 2024-11-26SINOSHENG SHENZHEN GENE IND DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411129534.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Traditional treatments for liver cancer have serious side effects and limitations, especially in advanced or metastatic liver cancer, and the complexity and variation of liver cancer antigens make it difficult to accurately identify and target key antigens on the surface of non-secretory cells, hindering The effective attack of immune cells on tumors has led to a high recurrence rate of liver cancer.

Method used

A specific vaccine is prepared by extracting and fully exposing whole membrane proteins from the patient's autologous liver cancer cells and mixing them with aluminum hydroxide adjuvant to activate the immune response to liver cancer, combined with traditional treatments to improve efficacy and prevent recurrence.

Benefits of technology

Significantly improve immune response ability, prevent postoperative recurrence, control the progression of advanced liver cancer, prolong survival, have good tolerance and safety, can work in concert with other anti-cancer treatment methods, and provide personalized treatment plans.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a specific vaccine for treating or preventing primary liver cancer and a preparation method thereof, and aims to improve the immunotherapy effect of liver cancer. The method comprises the following steps: firstly, separating and culturing liver cancer cells from liver tumor tissues of a patient, and performing passage to obtain high-purity cells; and then, extracting high-purity liver cancer whole membrane protein from the cells by adopting digestion and multi-stage centrifugation technologies. And then, accurately mixing the whole membrane protein with an aluminum hydroxide adjuvant to prepare a stable personalized vaccine with strong immunogenicity. The vaccine is given to a patient in a subcutaneous injection mode to stimulate the specific immune response of an organism to liver cancer cells, postoperative recurrence is prevented, and advanced liver cancer progression is controlled. Clinical results show that the vaccine can significantly improve the level of a specific IgG antibody and prolong the lifetime of a patient, no serious toxic or side effect is observed, and the vaccine shows good safety and treatment potential. The invention provides a new treatment choice for liver cancer patients, and particularly has obvious advantages in the aspects of improving the survival rate and the life quality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of tumor-specific vaccines, and in particular to a specific vaccine for treating or preventing primary liver cancer and a preparation method thereof. Background Art

[0002] Traditional treatments for malignant tumors, including surgery, chemotherapy, radiotherapy, and various targeted therapies, all have serious side effects and limitations. Tumor immunotherapy is a new anti-tumor method developed in recent years. It is an immunotherapy and prevention method that achieves the rejection or killing of tumor cells by regulating the patient's own immunity. When immunotherapy is used in combination with other anti-tumor therapies such as surgery, chemotherapy, or radiation, it achieves an internal and external anti-tumor effect.

[0003] The basic requirement of tumor immunotherapy based on cell immunity and antigen-antibody is that the tumor antigen (mainly protein antigen) is different from that of normal tissue. It can be different protein expression from the tumor or the antigen protein expression in tumor cells is significantly increased while the corresponding normal tissue expression is low. Another more important basic requirement is that the tumor antigen must be on the surface of the tumor cell. It cannot be in the cell because the corresponding immune cells or the corresponding antibodies cannot contact the intracellular antigen and cannot produce an immune response; it cannot be a secretory protein, so that the immune response occurs in tissues outside the tumor, which not only cannot play a role in treating tumors but also causes side effects. ATP of liver cancer is a secretory protein. Although it meets the first basic requirement and its expression level increases in liver cancer, it cannot be used as a vaccine. Therefore, the targets of tumor immunotherapy are all on the surface of tumor cells, such as the popular chimeric antigen receptor T cell immunotherapy (CAR-T) and various anti-tumor antibody immunotherapy. The next major obstacle to tumor immunotherapy is that no tumor antigens that meet the above criteria have been found for most tumors, especially solid malignant tumors, liver cancer is one of them.

[0004] The current treatment of liver cancer faces severe challenges. Although traditional therapies such as surgery, chemotherapy, radiotherapy and targeted therapy have their own effects, they are generally limited by serious side effects, drug resistance and low efficiency for advanced or metastatic liver cancer. In particular, these methods have failed to effectively solve the problem of high recurrence rate of liver cancer after surgery. In addition, the ubiquitous presence of immunosuppressive factors in the tumor microenvironment, such as TGF-β and IL-10, and the immunosuppressive effects of tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), greatly hinder the effective attack of immune cells on tumors. In addition, the complexity and variation of liver cancer antigens, coupled with the defects of antigen presentation mechanism, make it difficult to accurately identify and target liver cancer-specific antigens, especially those non-secretory, cell-surface key antigens. This not only limits the selection of immunotherapy targets, but also increases the difficulty of finding liver cancer-specific therapeutic targets. Therefore, there is an urgent need for a new therapy that can overcome the above obstacles, accurately identify and activate immune responses to liver cancer-specific antigens, and reduce damage to normal tissues, so as to fill the gaps in existing treatment methods and achieve the goal of effective treatment and prevention of recurrence of liver cancer. Summary of the invention

[0005] The present invention provides a specific vaccine for treating or preventing primary liver cancer and a preparation method thereof, aiming to solve the limitations of existing liver cancer treatment methods in terms of specificity, efficacy and recurrence prevention; the vaccine is prepared by separating and culturing the patient's own liver cancer cells, then extracting and fully exposing most of the membrane proteins (whole membrane antigens) of the liver cancer cells, and adding a suitable adjuvant. It is used for the specific treatment of liver cancer and metastatic cancer at various stages, and is also used for the recurrence of liver cancer after cure. For example, the liver cancer tissue after surgical resection is used to prepare a vaccine to prevent the recurrence of liver cancer. It can also be used alone or in combination with traditional anti-tumor treatment methods such as surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy to treat liver cancer at various stages.

[0006] The first aspect of the present invention provides a method for preparing a specific vaccine for treating or preventing primary liver cancer, which comprises the following steps:

[0007] 1. Prepare single cell suspension from the patient's liver tumor tissue by aseptic operation, digest with type I collagenase, filter impurities, and collect liver cancer cells by centrifugation;

[0008] 2. The cells are resuspended, enriched, cultured, and passaged until the required cell number reaches 5-16×10^12;

[0009] 3. After washing the cells, a gentle method is used to destroy the cell membrane to release the cell contents, and unbroken cells and larger organelles are removed by centrifugation. The intact cells, cell nuclei and cell fragments are removed by a second centrifugation. The supernatant is collected by a third centrifugation, and the supernatant is centrifuged four times to collect the precipitate as the whole membrane protein component. The precipitate is washed with a homogenization buffer and resuspended to finally obtain a high-purity liver cancer whole membrane protein.

[0010] 4. Use the obtained liver cancer whole membrane protein alone or mix it with aluminum hydroxide adjuvant in the ratio of 300 μg membrane protein to 200 μL adjuvant according to the manufacturer's instructions, and shake it thoroughly to ensure that the whole membrane protein and the adjuvant are fully combined to obtain the product.

[0011] For the technical solution described above, in a further preferred case, the liver cancer tissue obtained from the patient in step 1 is liver cancer tissue in the central area of ​​the parenchyma that is actively growing and has no obvious necrosis and bleeding. In a further preferred case, the liver cancer tissue in step 1 is thoroughly rinsed with physiological saline at 0-4°C to remove blood and debris, and then cut into blocks.

[0012] For the technical solution described above, in a further preferred case, the digestion with type I collagenase described in step 1 is to digest the tissue blocks with a concentration of 0.05%-0.2% (w / v) type I collagenase at 35-37°C for 0.5-2 hours, and then filter to remove the undigested tissue blocks. In fact, the digestion conditions, including enzyme concentration, temperature and time, can affect the cell recovery rate, vitality and the success rate of subsequent experiments. The following are some recommended parameter ranges, which can achieve similar effects to "incubating with type I collagenase at 37°C for 1 hour", and those skilled in the art can choose according to the situation:

[0013] Slightly lower concentration and longer time: 0.05% (w / v) type I collagenase, 37°C, 2 hours.

[0014] Example conditions: 0.1% (w / v) type I collagenase, 37° C., 1 hour.

[0015] Slightly higher concentration for a shorter time: 0.2% (w / v) type I collagenase, 37°C, 30 minutes.

[0016] Temperature adjustment: 0.15% (w / v) type I collagenase, 35°C, 1 hour.

[0017] For the technical solution described above, in a further preferred case, the centrifugation described in step 1 is to collect the cell precipitate at 200-400×g for 3-10 minutes. In the process of preparing single cell suspension from liver tumor tissue, centrifugation is to separate cells from digestion fluid and other cell debris. This parameter setting is intended to balance cell recovery efficiency and cell viability. If the speed or time is changed, the following are some possible parameter ranges, which can still achieve similar cell recovery and purification effects, and those skilled in the art can choose according to the situation: 200x g, 10 minutes, or 400x g, 3-5 minutes, etc.

[0018] For the technical solution described above, in a further preferred case, the culture medium used for cell resuspension, enrichment culture and passaging in step 2 is: RPMI1640 culture medium containing 8-12% (w / v) calf serum and 0.8-1.2% (w / v) penicillin-streptomycin.

[0019] For the technical solution described above, in a further preferred case, the method for destroying the cell membrane in step 3 is to add a homogenization buffer to the cell pellet, and freshly add an appropriate amount of a mixture of protease and phosphatase inhibitors to the homogenization buffer before use, and then use ultrasonic disruption.

[0020] For the technical solution described above, in a further preferred case, the homogenization buffer described in step 3 is generally used to protect the integrity and stability of cell membrane proteins and prevent protein degradation. In order to achieve an effect similar to that of the embodiment, the components of the homogenization buffer and their amount ranges can be adjusted as follows: sucrose is 200mM-300mM; EDTA is 0.5mM-2mM; Tris-HCl is 5mM-20mM, pH 7.0-7.4; in the embodiment, in order to achieve the best effect, the buffer composed of 250mM sucrose, 1mM EDTA, and 10mM Tris-HCl is selected, and the pH is 7.2.

[0021] For the technical solution described above, in a further preferred case, the protease and phosphatase inhibitor cocktail described in step 3 uses a commercially available protease and phosphatase inhibitor cocktail, which is added to the buffer at the ratio recommended by the product manual. The specific ratio may vary depending on the manufacturer and product type, but it is usually added at a ratio of 1:100 to 1:1000. In the embodiment, 50 μL of fresh protease and phosphatase inhibitor cocktail (protease and phosphatase inhibitor cocktail, Beyotime Biotechnology) is added to 5 mL of sterile homogenization buffer at a volume ratio of 1%.

[0022] For the technical solution described above, in a further preferred case, in the process of preparing the liver cancer cell total membrane protein in step 3, the multiple centrifugation steps involved and their conditions and purposes are as follows:

[0023] ① The centrifugation in step 3 to remove unbroken cells and larger organelles is performed at 500-1000×g for 5-15 minutes; the embodiment uses 800×g for 10 minutes to preliminarily purify the cell homogenate.

[0024] ② In step 3, the whole membrane protein component in the supernatant is collected by secondary centrifugation at 1000-2000×g for 5-15 minutes at 4°C; the embodiment uses 1500×g, 4°C, and centrifugation for 10 minutes to further remove intact cells, cell nuclei and cell debris, and collect a purer cell homogenate supernatant.

[0025] ③ In step 3, the whole membrane protein components in the supernatant are collected by centrifugation three or four times at 80,000-120,000×g, 1-2 hours, 4°C; the embodiment uses 100,000×g, 4°C, and 1 hour. In order to concentrate the whole membrane protein by ultracentrifugation, remove the soluble protein and other smaller molecules in the supernatant, and obtain a precipitate rich in membrane protein.

[0026] ④ Step 3: Washing and resuspending the precipitate: Wash the precipitate with a homogenization buffer to remove possible contaminants, and resuspend it with PBS to prepare a higher purity total membrane protein solution.

[0027] These centrifugation steps are performed sequentially to gradually improve the purity of the whole membrane protein, ensuring that the final vaccine has good immunogenicity and safety. After each centrifugation, it is decided whether to retain the supernatant or the precipitate according to the purpose to obtain the desired cell components. By precisely controlling the centrifugation speed and temperature, the different components of the cell can be effectively separated and purified, and finally high-quality whole membrane proteins can be obtained for vaccine preparation.

[0028] For the technical solution described above, in a further preferred case, the mixing ratio of the extracted liver cancer total membrane protein and the aluminum hydroxide adjuvant in step 4 is as follows: the amount of membrane protein is 200-400 μg; the amount of aluminum hydroxide adjuvant is 150-250 μL, the concentration is 0.5-0.7 mg / mL; the mass ratio of protein to aluminum hydroxide is 1:2-1:3; and the mixing time is 20-50 minutes.

[0029] When preparing a liver cancer cell full membrane protein vaccine, the amount of protein used, the amount of adjuvant, and the mixing conditions are all key parameters. The following are some possible parameter ranges that can achieve similar effects as described in the examples:

[0030] The amount of liver cancer cell membrane protein is 200-400 μg. The amount of protein in this range is usually enough to stimulate an immune response without causing excessive immune side effects.

[0031] Aluminum hydroxide adjuvant dose (Imject TM Alum Adjuvant) is 150-250 μL. The volume within this range can ensure that the adjuvant and protein are fully combined to provide a good immune stimulation effect.

[0032] The concentration of aluminum hydroxide adjuvant is 0.5-0.7 mg / mL. The concentration of adjuvant should be sufficient to support the adsorption of protein antigens, but avoid potential toxicity caused by excessive concentration.

[0033] Mixing conditions: The mass ratio of protein to aluminum hydroxide is 1:2-1:3; mix for 20-40 minutes. Appropriate mixing time can ensure that the protein and adjuvant are evenly combined to form a stable complex.

[0034] Gentle shaking or magnetic stirring is used to ensure full contact between the protein and adjuvant during the mixing process to form a stable vaccine formulation.

[0035] The parameter range of step 4 above may need to be adjusted according to specific experimental conditions and objectives. In actual operation, it may be necessary to determine the optimal vaccine preparation conditions through preliminary experiments to ensure the safety and effectiveness of the vaccine. The parameters selected in the following examples are: 300 μg of liver cancer cell membrane protein is added with 200 μL (equivalent to 120 μg) of aluminum hydroxide adjuvant (concentration of 0.6 mg / ml), and shaken and mixed for 30 minutes.

[0036] The second aspect of the present invention provides a specific vaccine for treating or preventing primary liver cancer prepared by the method described above. The vaccine is used to specifically treat liver cancer at all stages and metastatic cancer, and is also used for recurrence of liver cancer after cure. It can also be used alone or in combination with traditional anti-tumor treatment methods such as surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy to treat liver cancer at all stages.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] 1. Significantly enhance immune response: The present invention uses the patient's own liver cancer cell full membrane protein as an antigen to prepare liver cancer full membrane protein antigen, which can specifically activate the body's immune system and induce the production of high levels of specific IgG antibodies, significantly enhancing the immune recognition and clearance capabilities of liver cancer cells.

[0039] 2. Prevention of postoperative recurrence: Among patients undergoing radical liver cancer resection surgery, no recurrence was observed during an average follow-up of 38.3 months after vaccination with the vaccine of the present invention, indicating that the vaccine has significant advantages in preventing postoperative recurrence.

[0040] 3. Control the progression of advanced liver cancer: For patients with advanced liver cancer, the vaccine of the present invention has shown the ability to control tumor growth and metastasis. The tumors of some patients have been significantly reduced, and even lung metastases have disappeared, demonstrating its potential for the treatment of advanced liver cancer.

[0041] 4. Prolonged survival: The survival time of advanced patients treated with the vaccine of the present invention exceeds clinical expectations, and the survival time is significantly prolonged compared with advanced liver cancer patients who have not been treated or have only received conventional treatment.

[0042] 5. Good tolerability and safety: The vaccine of the present invention shows good safety and tolerability, with only mild side effects such as mild local reactions and short-term low-grade fever, and no reports of serious toxic side effects, which improves the patients' quality of life and treatment compliance.

[0043] 6. Personalized treatment: The present invention utilizes the patient's own tumor cells to prepare vaccines, achieving truly personalized treatment that can better match the unique immune needs of each patient and has higher treatment accuracy and effectiveness compared to universal vaccines or drugs.

[0044] 7. Synergistic therapeutic effect: The vaccine of the present invention can work synergistically with existing immunotherapy and other anti-cancer treatment methods to jointly enhance the therapeutic effect and provide patients with a multi-dimensional treatment plan. DETAILED DESCRIPTION

[0045] The present invention will be further described below in conjunction with embodiments, but it should be understood that the protection scope of the present invention is not limited by the embodiments.

[0046] In the present invention, unless otherwise specified, percentages and percentage contents are all by mass. Unless otherwise specified, the experimental methods used are all conventional methods, and the materials and reagents used can be purchased from commercial sources.

[0047] Example 1

[0048] Technical solution for the preparation of liver cancer cell whole membrane protein specific vaccine:

[0049] 1 Isolation and culture of liver cancer cells

[0050] From the liver tumor tissue obtained by liver puncture or surgical resection, 5-10 g of liver tumor tissue was taken from the center of the liver cancer tumor parenchyma (the active growth area was selected in the liver cancer parenchyma, avoiding obvious necrosis and bleeding areas), rinsed with normal saline (4°C) for 3 times, cut into pieces of about 2 mm, incubated with type I collagenase at 37°C for 1 hour, filtered through a stainless steel mesh, and centrifuged for 5 minutes (300 x g).

[0051] 2. Subculture

[0052] The cell pellet was suspended in RPMI1640 culture medium (with 10% calf serum and 1% penicillin-streptomycin), cultured in a 10 cm culture dish, and subcultured every 72 hours. On the 12th day (4×72 hours), the culture medium was removed, and the cells were rinsed 3 times with TBS (Tris-buffered saline), and the cell layer was scraped off and placed in 15 mL of TBS. After three subcultures, purified liver tumor cells were obtained, and the total number of cells obtained was 5-16×10^12 liver cancer cells.

[0053] 3 Extraction of total membrane proteins from liver cancer cells

[0054] The whole process was performed aseptically. Wash the collected cells with 5 mL of sterile PBS at 0-4°C, centrifuge at 800 × g for 5 minutes at 4°C and aspirate the PBS. Add 5 mL of sterile homogenization buffer (250 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl buffer, pH to 7.2) at 4°C, and add fresh protease and phosphatase inhibitor cocktail (protease and phosphatase inhibitor cocktail from Beyotime Biotechnology) 50μL, use ultrasonic homogenizer to homogenize and break the cells on ice, remove unbroken cells and large organelles such as nuclei by centrifugation at 1500×g for 10 minutes, transfer the homogenate to a fresh 1.5mL Ep tube, and centrifuge twice at 700×g for 10 minutes at 4°C to remove intact cells, nuclei and cell debris. Collect the supernatant and discard the precipitate. Centrifuge the supernatant three times at 100,000×g for one hour at 4°C, and aspirate the supernatant. Wash the precipitate with homogenization buffer and re-centrifuge it four times at 100,000×g for one hour at 4°C. Aspirate the supernatant, resuspend the precipitate with 1mL of PBS on ice (0-4°C), and then analyze the protein concentration, divide it into 3 equal parts (each part contains approximately 300μg-600μg protein), and the extracted whole membrane protein can be used to prepare vaccines immediately, or it can be stored at -80°C for preparation before treatment.

[0055] 4 Preparation of liver cancer cell whole membrane protein vaccine

[0056] The extracted liver cancer cell membrane protein (about 300 μg) was adjusted to 200 μL (equivalent to 120 μg) of aluminum hydroxide adjuvant (Imject TM Alum Adjuvant was purchased from Beijing Solebow Technology Co., Ltd. at a concentration of 0.6 mg / ml, and was shaken and mixed for 30 minutes to allow the aluminum adjuvant to fully adsorb the membrane protein antigen. So far, the preparation of the liver cancer cell full membrane protein vaccine has been completed.

[0057] The vaccine can be used immediately or stored at -20°C for later use depending on the patient's treatment status. When used, one dose of the vaccine is injected subcutaneously on the surface of the deltoid muscle. The other two doses are injected subcutaneously two weeks and four weeks later, respectively.

[0058] Example 2

[0059] Check for antibodies to liver cancer cell full membrane protein-specific vaccines (IgG antibody test)

[0060] 1. Analytical methods

[0061] The level of specific IG antibodies after immunization was checked using an IgG antibody detection kit (purchased from Promega). Two weeks after vaccination, 5 mL of blood was drawn from the patient to extract serum. A 96-well plate was coated with membrane protein at a concentration of 0.5 μg / mL and incubated overnight at 4°C. Wash and block with blocking solution for 30 minutes before use, and wash off the blocking solution. The separated serum was serially diluted in PBS to 1:10, 1:100, 1:1000, 1:10000, 1:100000, and 1:1000000, and then added to a 96-well plate in sequence, with 3 wells for each dilution. Buffer was added to the other 3 wells as a control. Then incubate at 37°C for 1 hour. After washing, the plate was incubated with HRP-labeled anti-human IgG at 37°C for 1 hour, and the reaction was stopped after the substrate solution was added and incubated for 30 minutes. The plate was incubated at OD 450 The cut-off value is defined as the OD of the buffer control. 450 Twice the value.

[0062] 2 Analysis results

[0063] Results of IgG antibody tests in serum samples of five patients who had received the specific liver cancer whole membrane protein vaccine: IgG antibodies were maintained at a significantly increased level at a serum dilution ratio of more than 1:10000, indicating that the IgG antibody titer was very high, which showed that the liver cancer whole membrane protein vaccine could effectively induce the production of a large number of specific IgG antibodies; at 1:100000 IgG antibodies dropped to about 1 / 3 of the highest value but were still significantly higher than the cutoff value, and at 1:1000000 IgG antibodies were close to the control value, indicating that even at a higher dilution, the antibodies remained at a high level, showing good antibody affinity and persistence. The conclusion is that the liver cancer whole membrane protein vaccine can induce a significant increase in specific IgG antibodies, and the test results are shown in Table 1.

[0064] Table 1 OD of different serum dilution ratios 450 Value (3 holes)

[0065] 1:10 1:100 1:1000 1:10000 1:100000 1:1000000 Patient 1 3.1 3.3 3.1 2.9 1.2 0.41 Patient 2 2.8 2.9 2.7 2.4 1.4 0.20 Patient 3 3.5 3.0 3.2 2.8 1.0 0.18 Patient 4 2.6 3.7 3.5 3.1 1.3 0.23 Patient 5 3.8 4.1 3.8 3.0 0.9 0.21 Buffer control 0.21 0.19 0.24 0.20 0.21 0.20

[0066] In summary, the data in Table 1 strongly support the ability of the liver cancer full membrane protein vaccine to induce specific IgG antibodies. After vaccination, the antibody titers of all patients participating in the trial increased to more than ten times that of the control group, showing the great potential of the vaccine in the field of immunotherapy. However, despite individual differences, this result emphasizes the general effectiveness of the vaccine in increasing antibody levels.

[0067] Example 3

[0068] Specific implementation methods and clinical effects

[0069] Since March 2019, 8 patients with liver cancer have been treated with a specific liver tumor cell whole membrane protein vaccine, with significant clinical effects and no obvious toxic side effects.

[0070] After radical resection of liver cancer, four patients used the excised liver cancer tissue to prepare specific liver tumor cell whole membrane protein vaccines according to the method described in Example 1. The vaccines were subcutaneously injected two weeks, four weeks and six weeks after surgery to prevent postoperative recurrence of liver cancer. The average follow-up time was 38.3 months (29 months to 49 months). As of April 2024, none of the four patients had recurred, proving the significant efficacy of the vaccine in preventing recurrence.

[0071] Four patients with advanced liver cancer had extensive tumor spread in the liver, and two patients had lung metastasis. Liver tissue removed by puncture was isolated, cultured and amplified for liver cancer cells, and then used to prepare liver tumor cell full membrane protein vaccine. Three patients had significantly reduced liver tumor size after vaccine treatment in combination with other immunotherapy (the total maximum diameter was reduced to 1 / 3, 1 / 2, and 2 / 3 of the size before treatment, respectively, showing the vaccine's effective inhibition of tumor growth). One patient with lung metastasis had lung metastasis disappear (indicating that the vaccine helps control distant metastasis). The three patients were followed up as of April 2024, 14, 25, and 28 months after vaccination, respectively, and are still alive (this largely exceeds the clinical expected survival of many patients with advanced liver cancer. In particular, considering that the tumor size of two of the patients was significantly reduced and the lung metastasis of one patient disappeared, these signs indicate that vaccine treatment may have had a positive impact on the survival of patients and prolonged their lives). Another patient died of tumor spread 9 months after vaccine treatment, although there was no significant improvement in the number and size of tumors after vaccine treatment, but his physical and mental state improved significantly during the treatment period.

[0072] All patients had no serious side effects after treatment with the specific liver tumor cell full membrane protein vaccine. Six patients had mild redness and swelling at the injection site 24 hours after vaccination, which recovered after 3 to 4 days. Three patients had a low fever (below 38°C), which also recovered within 3 to 4 days.

[0073] According to the above clinical information analysis:

[0074] 1. This clinical study preliminarily confirmed the safety and effectiveness of specific liver tumor cell whole membrane protein vaccine in preventing postoperative recurrence of liver cancer and controlling the progression of advanced liver cancer.

[0075] 2. Vaccines can not only significantly reduce the risk of recurrence, but also cooperate with other treatments to shrink tumors and even eliminate distant metastases, providing patients with better quality of life and the possibility of prolonging survival.

[0076] 3. The low incidence of side effects and mild adverse reactions further highlight the clinical application value of this vaccine.

[0077] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A method for preparing a specific vaccine for treating or preventing primary liver cancer, characterized in that: The steps include: (1) Single cell suspension was prepared from the patient's liver tumor tissue by aseptic operation, and liver cancer cells were collected by digestion with type I collagenase, filtration of impurities, and centrifugation; (2) The cells are resuspended, enriched, and passaged until the desired cell number reaches 5-16×10^12; (3) After washing the cells, a gentle method is used to disrupt the cell membrane to release the cell contents, and unbroken cells and larger organelles are removed by centrifugation. The intact cells, nuclei, and cell debris are removed by a second centrifugation. The supernatant was collected by three centrifugations, and the supernatant was collected by four centrifugations as the precipitate of the whole membrane protein component. The precipitate was washed with homogenization buffer and resuspended with PBS to obtain the whole membrane protein of liver cancer. (4) The obtained liver cancer total membrane protein is used alone or mixed with aluminum hydroxide adjuvant to fully prepare the product.

2. The method according to claim 1, characterized in that: The liver cancer tissue obtained from the patient in step (1) is liver cancer tissue in the central area of ​​the body that is actively growing and has no obvious necrosis and bleeding.

3. The method according to claim 1, characterized in that The digestion with type I collagenase in step (1) is to digest the tissue blocks with type I collagenase at a concentration of 0.05%-0.2% (w / v) at 35-37° C. for 0.5-2 hours, and then filter to remove the undigested tissue blocks.

4. The method according to claim 1, characterized in that: The centrifugation in step (1) is performed at 200-400×g for 3-10 minutes to collect the cell precipitate.

5. The method according to claim 1, characterized in that The culture medium used for the cell resuspension, enrichment culture and passage in step (2) is: RPMI1640 culture medium containing 8-12% (w / v) calf serum and 0.8-1.2% (w / v) penicillin-streptomycin.

6. The method according to claim 1, characterized in that The method for destroying the cell membrane in step (3) is to add a homogenization buffer to the cell pellet, and freshly add an appropriate amount of a mixture of protease and phosphatase inhibitors to the homogenization buffer before use, and then use ultrasonic disruption; and the homogenization buffer is composed of sucrose of 200mM-300mM; EDTA of 0.5mM-2mM; Tris-HCl of 5mM-20mM, pH 7.0-7.

4.

7. The method according to claim 1, characterized in that The protease and phosphatase inhibitor cocktail described in step (3) is added to the buffer at a ratio of 1:100 to 1:1000.

8. The method according to claim 1, characterized in that The centrifugation conditions of step (3) are as follows: ① The centrifugation in step (3) to remove unbroken cells and larger organelles is performed at 500-1000×g for 5-15 minutes; ② Step (3) The total membrane protein component in the supernatant is collected by secondary centrifugation at 1000-2000×g for 5-15 minutes; ③ Step (3) The total membrane protein component in the supernatant is collected by centrifugation three or four times at 80,000-120,000×g for 1-2 hours.

9. The method according to claim 1, characterized in that: The ratio of mixing the extracted liver cancer total membrane protein and aluminum hydroxide adjuvant in step (4) is as follows: 200-400 μg of membrane protein; 150-250 μL of aluminum hydroxide adjuvant, concentration 0.5-0.7 mg / mL; mass ratio of protein to aluminum hydroxide: 1:2-1:3; mixing time 20-50 minutes.

10. A specific vaccine for treating or preventing primary liver cancer prepared by the method of claim 1.